Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEBNASDAQ:EQNASDAQ:OBSVNASDAQ:PHAS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$1.71-5.8%$1.23$0.80▼$3.08$70.05M-0.9818,962 shs10,666 shsEQEquillium$0.33+2.7%$0.37$0.27▼$1.50$11.68M1.86438,426 shs40,195 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs300 shsPHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shs9.65 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals-5.80%+20.07%+57.87%+67.16%-28.96%EQEquillium+2.67%-3.96%-8.40%-30.82%-50.60%OBSVObsEva0.00%0.00%0.00%0.00%0.00%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%+6,910.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANEBAnebulo Pharmaceuticals2.2536 of 5 stars3.53.00.00.00.01.70.0EQEquillium1.8642 of 5 stars3.22.00.00.01.11.70.6OBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 3.00Buy$5.50222.58% UpsideEQEquillium 2.33Hold$3.00817.43% UpsideOBSVObsEva 0.00N/AN/AN/APHASPhaseBio Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PHAS, ANEB, EQ, and OBSV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ANEBAnebulo PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.15 per shareN/AEQEquillium$41.10M0.28N/AN/A$0.54 per share0.61OBSVObsEvaN/AN/AN/AN/A$0.41 per shareN/APHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.20M-$0.26N/A∞N/AN/A-90.11%-84.53%N/AEQEquillium-$8.07M-$0.39N/AN/AN/A-19.62%-74.34%-46.75%8/6/2025 (Estimated)OBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/APHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/ALatest PHAS, ANEB, EQ, and OBSV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q3 2025ANEBAnebulo Pharmaceuticals-$0.05-$0.04+$0.01-$0.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A25.2925.29EQEquilliumN/A2.702.70OBSVObsEvaN/A0.610.61PHASPhaseBio PharmaceuticalsN/A0.470.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%EQEquillium27.05%OBSVObsEva17.52%PHASPhaseBio Pharmaceuticals49.02%Insider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%EQEquillium31.60%OBSVObsEva14.40%PHASPhaseBio Pharmaceuticals9.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals441.09 million7.97 millionNot OptionableEQEquillium4035.72 million24.43 millionNot OptionableOBSVObsEva5077.97 million66.74 millionNot OptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionablePHAS, ANEB, EQ, and OBSV HeadlinesRecent News About These CompaniesPhio Pharma announces strategic initiative to create awareness of the comprehensive INTASYL siRNA portfolioJune 9, 2025 | pharmabiz.comPTicagrelor antidote safely, effectively restores platelet function and treats bleedingApril 1, 2025 | msn.comMedPharm appoints Bill Humphries as new CEOFebruary 6, 2025 | msn.comMedpharm Appoints Chief Executive OfficerFebruary 4, 2025 | contractpharma.comCPhaseBio Pharmaceuticals Inc.October 19, 2024 | thestreet.comPhiladelphia-area life sciences industry nears 900 layoffs since 2022October 11, 2024 | bizjournals.comPhaseBio Pharmaceuticals, Inc. (PHASQ)August 3, 2024 | ca.finance.yahoo.comModified Release Neurology Therapeutics Report 202…February 19, 2024 | pharmiweb.comPVelia Therapeutics Appoints Michael York as Chief Business OfficerDecember 14, 2023 | finance.yahoo.comLeading innovators in GLP-1 analogues for the pharmaceutical industryNovember 6, 2023 | pharmaceutical-technology.comPAlcami Announces CEO TransitionJune 5, 2023 | finance.yahoo.com8-K: PhaseBio Pharmaceuticals IncMay 12, 2023 | marketwatch.comAbsci Corporation: Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating ResultsMarch 31, 2023 | finanznachrichten.deBioCryst Pharmaceuticals, Inc.: BioCryst Appoints Dr. Nancy Hutson as Chair of the BoardMarch 31, 2023 | finanznachrichten.deBioCryst Appoints Dr. Nancy Hutson as Chair of the BoardMarch 31, 2023 | finance.yahoo.comCardiomyopathy Medication Market Size and Forecast till 2031March 22, 2023 | marketwatch.comCardiomyopathy Medication Market Emerging Demand and Drive Growth by 2028 with Top Countries DataFebruary 28, 2023 | marketwatch.comJi Xing obtains global rights to cardiovascular candidate from PhasebioFebruary 9, 2023 | bioworld.comBBankrupt PhaseBio settles with investor-partner, handing off late-stage drugJanuary 18, 2023 | endpts.comESFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio PharmaceuticalsJanuary 17, 2023 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeLululemon, UNH, Enphase: Bad News, Good Opportunity?By Thomas Hughes | June 17, 2025View Lululemon, UNH, Enphase: Bad News, Good Opportunity?ASML’s AI Edge: How Its EUV Tech Is Creating a New MonopolyBy Jeffrey Neal Johnson | June 10, 2025View ASML’s AI Edge: How Its EUV Tech Is Creating a New MonopolyThis Banking Giant Just Got a $90 Price Target UpgradeBy Gabriel Osorio-Mazilli | June 6, 2025View This Banking Giant Just Got a $90 Price Target UpgradeNektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?By Leo Miller | June 28, 2025View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?PHAS, ANEB, EQ, and OBSV Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$1.70 -0.11 (-5.80%) As of 07/3/2025 02:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Equillium NASDAQ:EQ$0.33 +0.01 (+2.67%) Closing price 07/3/2025 03:20 PM EasternExtended Trading$0.33 0.00 (0.00%) As of 07/3/2025 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.PhaseBio Pharmaceuticals NASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case How a Government Loan Changes the Game for Plug Power Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
